References
- Rhodes CJ, Davidson A, Gibbs JS, Wharton J, Wilkins MR. Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther 2009;121:69–88.
- Tu L, Dewachter L, Gore B, Fadel E, Dartevelle P, Simonneau G, et al. Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. Am J Respir Cell Mol Biol 2011;45:311–22.
- Shimizu H, Takahashi M, Takeda S, Inoue S, Fujishiro J, Hakamata Y, et al. Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation 2004;77:1661–7.
- Kanzaki H, Ouchida M, Hanafusa H, Yano M, Suzuki H, Aoe M, et al. Single nucleotide polymorphism of the AXIN2 gene is preferentially associated with human lung cancer risk in a Japanese population. Int J Mol Med 2006;18:279–84.
- Zheng Y, Li M, Zhang Y, Shi X, Li L, Jin M. The effects and mechanisms of mycophenolate mofetil on pulmonary arterial hypertension in rats. Rheumatol Int 2010;30:341–8.
- Lipke DW, Arcot SS, Gillespie MN, Olson JW. Temporal alterations in specific basement membrane components in lungs from monocrotaline-treated rats. Am J Respir Cell Mol Biol 1993;9:418–28.
- Hessel MH, Steendijk P, den Adel B, Schutte CI, van der Laarse A. Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am J Physiol Heart Circ Physiol 2006;291:H2424–30.
- Zhao YD, Courtman DW, Ng DS, Robb MJ, Deng YP, Trogadis J, et al. Microvascular regeneration in established pulmonary hypertension by angiogenic gene transfer. Am J Respir Cell Mol Biol 2006;35:182–9.
- Dorfmuller P, Humbert M, Perros F, Sanchez O, Simonneau G, Muller KM, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007;38:893–902.
- Selimovic N, Bergh CH, Andersson B, Sakiniene E, Carlsten H, Rundqvist B. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J 2009; 34:662–8.
- El Chami H, Hassoun PM. Immune and inflammatory mechanisms in pulmonary arterial hypertension. Prog Cardiovasc Dis 2012;55:218–28.
- Haug C, Schmid-Kotsas A, Linder T, Bachem MG, Gruenert A, Rozdzinski E. Influence of hepatocyte growth factor, epidermal growth factor, and mycophenolic acid on endothelin-1 synthesis in human endothelial cells. Nephrol Dial Transplant 2001;16:2310–16.
- Haug C, Schmid-Kotsas A, Linder T, Jehle PM, Bachem MG, Gruenert A, et al. The immunosuppressive drug mycophenolic acid reduces endothelin-1 synthesis in endothelial cells and renal epithelial cells. Clin Sci 2002;103(Suppl 48):76S–80S.
- Wedgwood S, Devol JM, Grobe A, Benavidez E, Azakie A, Fineman JR, et al. Fibroblast growth factor-2 expression is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. Pediatr Res 2007;61:32–6.
- Benisty JI, McLaughlin VV, Landzberg MJ, Rich JD, Newburger JW, Rich S, et al. Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. Chest 2004;126:1255–61.